Trial · NCT02704962
Olanzapine vs. Low-dose Olanzapine Plus Trifluoperazine
NCT02704962, Phase 4, Completed, Kaohsiung Kai-Suan Psychiatric Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Olanzapine vs. Low-dose Olanzapine Plus Trifluoperazine. Trials, record NCT02704962. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02704962
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Olanzapine vs. Low-dose Olanzapine Plus Trifluoperazine
- NCT number
- NCT02704962
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 94 participants, actual
- Lead sponsor
- Kaohsiung Kai-Suan Psychiatric Hospital
- Conditions
- Schizophrenia
- Interventions
- full-dose olanzapine
- First posted
- 2016-03-10
- Last updated
- 2016-03-10
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The changes in the Positive and Negative Syndrome Scale (PANSS) scores from baseline to the end of the study. | The PANSS was rated at baseline, and again at weeks 1, 2, 3, 4, and 6 (or on early termination). | |
| Secondary | The changes in the Clinical Global Impression-Severity (CGI-S) scores from baseline to the end of the study. | The CGI-S was rated at baseline, and again at weeks 1, 2, 3, 4, and 6 (or on early termination). | |
| Secondary | The changes in the Calgary Depression Scale for Schizophrenia (CDSS) scores from baseline to the end of the study. | The CDSS was rated at baseline, and again at weeks 1, 2, 3, 4, and 6 (or on early termination). | |
| Secondary | The changes in the Global Assessment of Functioning (GAF) scores from baseline to the end of the study. | The GAF was rated at baseline, and again at weeks 1, 2, 3, 4, and 6 (or on early termination). | |
| Secondary | The changes in the Short-Form 36 (SF-36) scores from baseline to week 6. | The SF-36 was rated at baseline and again at week 6. | |
| Secondary | The changes in the Mini Mental State Examination (MMSE) scores from baseline to week 6. | The MMSE was rated at baseline and again at week 6. | |
| Secondary | The changes in the Simpson-Angus Rating Scale (SAS) scores from baseline to the end of the study. | The SAS was rated at baseline, and again at weeks 1, 2, 3, 4, and 6 (or on early termination). | |
| Secondary | The changes in the Abnormal Involuntary Movement Scale (AIMS) scores from baseline to the end of the study. | The AIMS was rated at baseline, and again at weeks 1, 2, 3, 4, and 6 (or on early termination). | |
| Secondary | The changes in the Barnes Akathisia Scale (BAS) scores from baseline to the end of the study. | The BAS was rated at baseline, and again at weeks 1, 2, 3, 4, and 6 (or on early termination). | |
| Secondary | The changes in the UKU Side-effects Rating Scale (UKU) scores from baseline to the end of the study. | The UKU was rated at baseline, and again at weeks 1, 2, 3, 4, and 6 (or on early termination). |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02704962
GET https://conductscience.org/api/trials/v1/NCT02704962/registered